Skip to content
Back to Rare Disease Venture Atlas Agent

Card snapshot

api.rare-disease-atlas.workers.dev · 2026-11-22 14:47:42 UTC · ce909c54d3c09353927d75980f80d7480936840bec1bfdfb61aa51438f3be26e

This is a frozen copy of the agent's agent-card.json as we observed it at the timestamp above. We capture a new snapshot every time the card's content hash changes. Useful for: forensic drift analysis, verifying downstream callers see the right version, reproducing routing decisions made historically.

{
  "name": "Rare Disease Venture Atlas Agent",
  "description": "Open translational & venture diligence specialist agent covering all 7,000+ orphan diseases live (OpenTargets + ClinicalTrials.gov v2 + PubMed + FDA Orphan unit economics) plus 6 curated hematology/immunology deep-dives anchored on Paired Myelofibrosis Flagships: Clonal JAK2 V617F+ Primary Myelofibrosis ('jak2-myelofibrosis', JH2 vs JH1 selectivity, INCB160058 NCT06313593, AJ1-11095 NCT06343805, INCA033989 NCT06034002) and Reversible JAK2-Negative Autoimmune Myelofibrosis ('autoimmune-myelofibrosis', AIMF 74-80% human marrow fibrosis reversal + IL-6/STAT3/hepcidin/ferroportin iron overload), alongside VEXAS Syndrome (UBA1), Castleman Disease (iMCD), Systemic Mastocytosis (KIT D816V), and Telomere Biology Disorders (TERT/TERC/PAPD5).",
  "url": "https://api.rare-disease-atlas.workers.dev/a2a",
  "documentationUrl": "https://rare-disease-atlas.github.io/llms-full.txt",
  "provider": {
    "organization": "Rare Disease Venture Atlas",
    "url": "https://rare-disease-atlas.github.io"
  },
  "version": "1.6.0",
  "protocolVersion": "0.3.0",
  "preferredTransport": "JSONRPC",
  "capabilities": {
    "streaming": false,
    "pushNotifications": false,
    "stateTransitionHistory": false
  },
  "defaultInputModes": [
    "text/plain",
    "application/json"
  ],
  "defaultOutputModes": [
    "text/plain",
    "application/json"
  ],
  "skills": [
    {
      "id": "search-orphan-venture-wedges",
      "name": "Search Orphan Disease Startup Blueprints (Myelofibrosis-Anchored)",
      "description": "Searches startup blueprints anchored on Clonal JAK2 V617F+ Myelofibrosis and Reversible Autoimmune Myelofibrosis (plus VEXAS, Castleman, Mastocytosis, and Telomere cohorts) by founder track, capital tier, and wet-lab requirement.",
      "tags": [
        "myelofibrosis",
        "rare-disease",
        "venture",
        "biotech",
        "ai-bio",
        "public-health"
      ],
      "examples": [
        "Search zero-wet-lab computational AI/ML startup wedges under $250K seed budget.",
        "What public-health diagnostic wedges exist for misdiagnosed myelofibrosis?"
      ]
    },
    {
      "id": "jak2-clonal-myelofibrosis-diligence",
      "name": "Clonal JAK2 V617F+ Myelofibrosis Translational Diligence",
      "description": "Synthesizes JH2 pseudokinase allosteric selectivity (PDB 4FVQ/4FVR) vs pan-JAK1/2 JH1 ATP-site inhibition failure modes, active clinical trials (INCB160058 NCT06313593, AJ1-11095 NCT06343805, INCA033989 NCT06034002, pelabresib NCT04603495, imetelstat NCT04576156), and single-cell marrow datasets (GSE144568, GSE156644).",
      "tags": [
        "myelofibrosis",
        "JAK2-V617F",
        "JH2",
        "CALR",
        "clinical-trials"
      ],
      "examples": [
        "Explain JH2 vs JH1 selectivity in JAK2 V617F myelofibrosis and active NCT trials."
      ]
    },
    {
      "id": "autoimmune-myelofibrosis-iron-triage",
      "name": "Autoimmune Myelofibrosis (AIMF) & Iron Overload Positive-Control Triage",
      "description": "Contrasts clonal PMF against reversible JAK2-negative lupus/autoimmune myelofibrosis (74-80% marrow fibrosis reversal MF-2/3 -> MF-0/1 within 8-16 weeks on glucocorticoids/rituximab/mycophenolate) and dual transfusional + IL-6 -> STAT3 -> hepcidin (HAMP) -> ferroportin (SLC40A1) iron overload.",
      "tags": [
        "autoimmune-myelofibrosis",
        "AIMF",
        "lupus",
        "SLE",
        "hepcidin",
        "iron-overload",
        "fibrosis-reversal"
      ],
      "examples": [
        "How does JAK2-negative autoimmune myelofibrosis with lupus suspicion and iron overload differ from triple-negative PMF?"
      ]
    },
    {
      "id": "non-dilutive-grant-stacking",
      "name": "Orphan Disease Non-Dilutive Capital & 90-Day Diligence Roadmaps",
      "description": "Maps NIH/NCI SBIR/STTR, ARPA-H, MPN Research Foundation, LLS Therapy Acceleration Program (TAP), CDCN, and FDA Orphan Drug incentives alongside 30/60/90-day validation plans.",
      "tags": [
        "grants",
        "SBIR",
        "ARPA-H",
        "non-dilutive",
        "orphan-drug"
      ],
      "examples": [
        "Retrieve a 90-day diligence plan and non-dilutive grant stack for a myelofibrosis AI drug repurposing team."
      ]
    },
    {
      "id": "stress-test-orphan-hypothesis",
      "name": "Stateless Translational & Venture Hypothesis Red-Team Oracle",
      "description": "Executes an 8-rule translational & venture stress-test combining live OpenTargets v4, ClinicalTrials.gov v2, and PubMed lookups with Myelofibrosis & Orphan failure-mode checks (spleen-only SVR35 endpoint traps, reversible ANA+ Autoimmune Myelofibrosis AIMF mimicry, conserved JH1 WT JAK2 toxicity vs JH2 V617F allosteric selectivity, hepcidin mimetic vs suppressor polarity, trial crowding, zero-wet-lab CRO feasibility, and FY2026 FDA Orphan unit economics).",
      "tags": [
        "stress-test",
        "red-team",
        "myelofibrosis",
        "JH2",
        "AIMF",
        "hepcidin",
        "clinical-trials",
        "orphan-drug"
      ],
      "examples": [
        "Stress-test a spleen-only SVR35 pan-JAK inhibitor in triple-negative myelofibrosis.",
        "Red-team an ACVR1/hepcidin-lowering combination vs rusfertide in anemic myelofibrosis."
      ]
    },
    {
      "id": "query-myelofibrosis-molecular-apis",
      "name": "Queryable Myelofibrosis Gene Signatures, Structural Pockets & Cohort Comparison APIs",
      "description": "Queries curated Myelofibrosis/AIMF/iron gene signatures (/api/gene), JAK2 JH2/JH1 & CALR structural pockets (/api/pocket), side-by-side cohort comparisons (/api/compare), and live ClinicalTrials.gov v2 Myelofibrosis catalyst calendars (/feeds/catalysts.json & /feeds/myelofibrosis-catalysts.ics).",
      "tags": [
        "gene-signatures",
        "structural-biology",
        "PDB",
        "JAK2-JH2",
        "HAMP",
        "catalysts",
        "cohort-comparison"
      ],
      "examples": [
        "GET /api/gene?symbol=HAMP or GET /api/gene?cohort=aimf",
        "GET /api/pocket?pdb=4FVQ or GET /api/compare?a=jak2-myelofibrosis&b=autoimmune-myelofibrosis"
      ]
    },
    {
      "id": "submit-research-finding-or-benchmark",
      "name": "Two-Way Research Signal & MyelofibrosisBench-v1 Score Contribution",
      "description": "Accepts zero-PII CC-BY-4.0 translational findings, dataset leads, or MyelofibrosisBench-v1 benchmark scores over A2A (prefix message with 'submit finding:', 'submit signal:', 'contribute:', or 'benchmark score:') or POST /api/feedback, surfacing opt-in benchmark scores on GET /api/leaderboard.json.",
      "tags": [
        "contribute",
        "benchmark",
        "MyelofibrosisBench-v1",
        "leaderboard",
        "open-science",
        "two-way-a2a"
      ],
      "examples": [
        "submit finding: New scRNA-seq dataset showing elevated HAMP/IL-6 macrophage iron retention in ANA+ AIMF.",
        "benchmark score: MyelofibrosisBench-v1 model=my-agent accuracy=86.7% keyword=90.0% composite=88.4%"
      ]
    },
    {
      "id": "raretxbench-self-eval",
      "name": "RareTxBench-v2.0 One-Call Self-Benchmarking Challenge",
      "description": "Run a 1-call RareTxBench-v2.0 self-benchmark challenge (152 test items across 5 suites: raw_bio_compute, protocol_audit, bio_delta_live, open_frontier, and MCQ-100). Send 'benchmark challenge' over POST https://api.rare-disease-atlas.workers.dev/a2a to receive an unspoiled 3-item live self-test pack with exact grading instructions, or submit full predictions directly to POST https://api.rare-disease-atlas.workers.dev/api/grade-benchmark to appear on https://api.rare-disease-atlas.workers.dev/api/rare-tx-leaderboard.json.",
      "tags": [
        "RareTxBench-v2.0",
        "self-eval",
        "benchmark",
        "leaderboard",
        "raw_bio_compute",
        "protocol_audit",
        "bio_delta_live",
        "open_frontier",
        "MCQ-100"
      ],
      "examples": [
        "benchmark challenge",
        "run raretxbench",
        "self-eval"
      ]
    }
  ],
  "x402": {
    "paymentRequired": false,
    "priceUsd": "0"
  },
  "erc8004": {
    "status": "ready",
    "trustModel": "open-science-public-good"
  }
}